Biopharmaceutical company Biocon is planning to submit a request for approval of generic copies of the blockbuster ...

The biosimilars market is estimated to reach USD 66.9 billion by 2028 from USD 29.4 billion in 2023, at a CAGR of 17.8% ...

Biocon Biologics Ltd today announced that the U.S. Food and Drug Administration has approved Kirsty™ (Insulin Aspart-xjhz), ...

Biocon aims to introduce generic versions of the obesity drug Wegovy in India and Canada by late 2026 or early 2027, ...

Biocon is set to launch generic versions of Wegovy in India and Canada, aiming for market entry by late 2026 or early 2027.

By Rishika Sadam HYDERABAD (Reuters) -Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years, a top executive told Reuters, ...

Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years, a top executive told Reuters ...

Fundraising through qualified institutional placements (QIPs) saw a revival in June after a tepid first five months of 2025, ...

State Bank of India (SBI), the largest lender in the country, has launched a share sale to institutional investors to raise ...

The Nifty Pharma index experienced a slight decline of 0.32% on Wednesday, despite several stocks seeing gains throughout the day.

The global drug discovery services market is projected to grow at a CAGR of 15% from 2025 to 2030. This growth is driven by the increasing demand for outsourced drug discovery activities, advancements ...

HDFC Asset Management Company reported a 24% on-year jump in net profit to Rs 748 crore for the first quarter of the financial year 2026.